Cardior Pharmaceuticals

About:

Cardior Pharmaceuticals discovers and develops medicines and therapeutics for the treatment and prevention of heart disease.

Website: http://cardior.de/

Top Investors: HTGF | High-Tech Gruenderfonds, Bristol-Myers Squibb, EQT Life Sciences, Boehringer Ingelheim Venture Fund, Inkef

Description:

Cardior Pharmaceuticals is a biotechnology company that engages in the development of non-coding RNA based therapeutics for the treatment and prevention of heart disease. It focuses on developing CDR-132X, an oligonucleotide-based inhibitor of a molecular master switch (microRNA) controlling pathological alterations of the heart following stress or injury. Cardior Pharmaceuticals is a planned academic spin-off developing new therapeutics for the treatment and prevention of heart disease - the number one cause of death in the western world.